These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 29316830)

  • 1. Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae.
    Ni W; Li G; Zhao J; Cui J; Wang R; Gao Z; Liu Y
    Infect Dis (Lond); 2018 Jul; 50(7):507-513. PubMed ID: 29316830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia.
    Wei C; Ni W; Cai X; Cui J
    Infect Dis (Lond); 2015; 47(12):846-51. PubMed ID: 26167850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae.
    Tsala M; Vourli S; Daikos GL; Tsakris A; Zerva L; Mouton JW; Meletiadis J
    J Antimicrob Chemother; 2017 Jan; 72(1):172-180. PubMed ID: 27650184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pharmacodynamic simulation to evaluate tigecycline in treatment of nosocomial pneumonia caused by multidrug-resistant Acinetobacter baumannii.
    Ni WT; Liang BB; Cai Y; Liu YP; Bai N; Cui JC; Wang R
    Pak J Pharm Sci; 2014 May; 27(3):463-7. PubMed ID: 24811802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients.
    Balandin Moreno B; Fernández Simón I; Pintado García V; Sánchez Romero I; Isidoro Fernández B; Romera Ortega MA; Alcántara Carmona S; Pérez Redondo M; Galdos Anuncibay P
    Scand J Infect Dis; 2014 Mar; 46(3):175-80. PubMed ID: 24354959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae.
    Daly MW; Riddle DJ; Ledeboer NA; Dunne WM; Ritchie DJ
    Pharmacotherapy; 2007 Jul; 27(7):1052-7. PubMed ID: 17594211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: Should we get to the PK/PD root of the paradox?
    Del Bono V; Giacobbe DR; Marchese A; Parisini A; Fucile C; Coppo E; Marini V; Arena A; Molin A; Martelli A; Gratarola A; Viscoli C; Pelosi P; Mattioli F
    Virulence; 2017 Jan; 8(1):66-73. PubMed ID: 27430122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal empiric treatment for KPC-2-producing Klebsiella pneumoniae infections in critically ill patients with normal or decreased renal function using Monte Carlo simulation.
    Wang G; Yu W; Cui Y; Shi Q; Huang C; Xiao Y
    BMC Infect Dis; 2021 Mar; 21(1):307. PubMed ID: 33771113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Klebsiella pneumoniae: development of a mixed population of carbapenem and tigecycline resistance during antimicrobial therapy in a kidney transplant patient.
    Rodríguez-Avial C; Rodríguez-Avial I; Merino P; Picazo JJ
    Clin Microbiol Infect; 2012 Jan; 18(1):61-6. PubMed ID: 21722259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic effect of tigecycline, unlike that of Ceftazidime, is not influenced by whether the Klebsiella pneumoniae strain produces extended-spectrum β-lactamases in experimental pneumonia in rats.
    Goessens WH; Mouton JW; Ten Kate MT; Sörgel F; Kinzig M; Bakker-Woudenberg IA
    Antimicrob Agents Chemother; 2013 Jan; 57(1):643-6. PubMed ID: 23129049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli.
    Spanu T; De Angelis G; Cipriani M; Pedruzzi B; D'Inzeo T; Cataldo MA; Sganga G; Tacconelli E
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4516-8. PubMed ID: 22644031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae.
    Cojutti P; Sartor A; Righi E; Scarparo C; Bassetti M; Pea F
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic/pharmacodynamic modelling to evaluate the efficacy of various dosing regimens of ceftazidime/avibactam in patients with pneumonia caused by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae: a multicentre study in northern China.
    Kang Y; Zhou Q; Cui J
    J Glob Antimicrob Resist; 2021 Dec; 27():67-71. PubMed ID: 34428596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of tigecycline resistance in Klebsiella pneumoniae in a single patient.
    Al-Qadheeb NS; Althawadi S; Alkhalaf A; Hosaini S; Alrajhi AA
    Ann Saudi Med; 2010; 30(5):404-7. PubMed ID: 20697161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli.
    Docobo-Pérez F; Nordmann P; Domínguez-Herrera J; López-Rojas R; Smani Y; Poirel L; Pachón J
    Int J Antimicrob Agents; 2012 Mar; 39(3):251-4. PubMed ID: 22154856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tigecycline susceptibility in Klebsiella pneumoniae and Escherichia coli causing neonatal septicaemia (2007-10) and role of an efflux pump in tigecycline non-susceptibility.
    Roy S; Datta S; Viswanathan R; Singh AK; Basu S
    J Antimicrob Chemother; 2013 May; 68(5):1036-42. PubMed ID: 23335112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical issues for Klebsiella pneumoniae KPC-carbapenemase producing K. pneumoniae infections: a critical agenda.
    De Rosa FG; Corcione S; Cavallo R; Di Perri G; Bassetti M
    Future Microbiol; 2015; 10(2):283-94. PubMed ID: 25689539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections.
    Xie J; Roberts JA; Alobaid AS; Roger C; Wang Y; Yang Q; Sun J; Dong H; Wang X; Xing J; Lipman J; Dong Y
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections.
    Falagas ME; Vardakas KZ; Tsiveriotis KP; Triarides NA; Tansarli GS
    Int J Antimicrob Agents; 2014 Jul; 44(1):1-7. PubMed ID: 24602499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance.
    Ku YH; Chen CC; Lee MF; Chuang YC; Tang HJ; Yu WL
    J Microbiol Immunol Infect; 2017 Dec; 50(6):931-939. PubMed ID: 28716360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.